Our understanding of the mechanism by which the E3-19K protein from adenovirus (Ad) 2 targets major histocompatibility complex (MHC) class I molecules for retention in the endoplasmic reticulum (ER) is derived largely from studies of Ad serotype 2 (subgroup C). It is not well understood to what extent observations on the Ad2 E3-19K/MHC I association can be generalized to E3-19K proteins of other serotypes and subgroups. The low levels of amino acid sequence homology between E3-19K proteins suggest that these proteins are likely to manifest distinct MHC I binding properties. This information is important as the E3-19K/MHC I interaction is thought to play a critical role in enabling Ads to cause persistent infections. Here, we characterized interaction between E3-19K proteins of serotypes 7 and 35 (subgroup B), 5 (subgroup C), 37 (subgroup D), and 4 (subgroup E) and a panel of HLA-A, -B, and -C molecules using native gel, surface plasmon resonance (SPR), and flow cytometry. Results show that all E3-19K proteins exhibited allele-specificity towards HLA-A and -B molecules; this was less evident for Ad37 E3-19K. The allele-specificity for HLA-A molecules was remarkably similar for different serotypes of subgroup B as well as subgroup C. Interestingly, all E3-19K proteins characterized also exhibited MHC I locus-specificity. Importantly, we show that Lys 91 in the conserved region of Ad2 E3-19K targets the C-terminus of the α2-helix (MHC residue 177) on MHC class I molecules. From our data, we propose a model of interaction between E3-19K and MHC class I molecules. _____________________________________ 2 The abbreviations used are: Ad, adenovirus; MHC, major histocompatibility complex; ER, endoplasmic reticulum; CTL, cytotoxic T lymphocyte; SPR, surface plasmon resonance; β 2 m, β 2 -microglobulin; NK, natural killer; MIC A/B, MHC-I chain related proteins A and B; CMV, cytomegalovirus; Ig, immunoglobulin.
Ads are widespread in the human population, with at least 51 human serotypes (Ad1 to Ad51) known that are classified into six subgroups (A to F) (1, 2) . Following primary infection of the respiratory tract, Ads of subgroup C (the most commonly studied subgroup) can be recovered from stool for months, and even years, after the virus is no longer detected in nasopharyngeal specimens (3, 4) . It is believed that this is a manifestation of the ability of Ads to counteract host antiviral immune responses and establish persistent infections. Diseases caused by Ad infections are generally mild except in immunosuppressed individuals, such as AIDS patients and transplant recipients, in which case Ad infections can be fatal (5) (6) (7) (8) .
It was first shown that Ad2 could drastically decrease the expression of MHC class I molecules on Ad2-infected cells (9) (10) (11) . The E3-19K protein of Ad2 was found to be specifically responsible for this effect (11) . It is now understood that E3-19K binds directly to and retains MHC class I molecules in the ER. Consequently, E3-19K downregulates MHC class I molecules on Adinfected cells and protects cells from recognition and lysis by allospecific CTLs (9) (10) (11) (12) (13) (14) (15) (16) (17) . E3-19K-mediated suppressing effects on CTL activity were shown in Ad-infected human and mouse cells (15, 16, 18) . Moreover, in vivo data support a role for E3-19K in Ad infections (19) ; lungs of cotton rats infected with a mutant Ad containing a deletion of the E3-19K gene caused a more severe immunopathology than lungs infected with wildtype Ad. It was suggested that the absence of E3-19K in the mutant virus activated CTLs as part of the inflammatory response to the infection (19) . Thus, there is convincing evidence from in vitro and in vivo studies that E3-19K, through its association with MHC class I molecules, facilitates the undetected replication of the virus in infected host cells. This is thought to contribute to the ability of Ads to establish and maintain persistence (19) (20) (21) .
E3-19K is a type I transmembrane glycoprotein that comprises a N-terminus ERlumenal domain and a short C-terminus cytosolic tail. The ER-lumenal domain of E3-19K binds with high-affinity to the ER-lumenal domain of MHC class I molecules (12, (22) (23) (24) (25) (26) and the dilysine motif in the cytosolic tail of E3-19K provides the signal for localization in the ER (12, 27, 28 (30, 31) . It was also reported that Ad2 E3-19K coimmunoprecipitated more readily with HLA-A2 than HLA-B7 (32). Furthermore, it was shown previously that Ad2 and Ad19a E3-19K proteins of subgroups C and D, respectively, differ in their capacity to inhibit the trafficking of MHC class I molecules to the cell surface (12) . This kind of information on the MHC I binding function of E3-19K proteins of different Ad serotypes and subgroups is critical not only for our understanding of the structure/function relationship of E3-19K, but also because it is thought that the ability of a particular Ad serotype to replicate and establish persistent infection in host cells may depend on the avidity of its E3-19K protein for the HLA molecules present in the infected individual (21, 33) . There is therefore an epidemiological component to our understanding of Ad pathogenesis that can be probed from a systematic study of E3-19K function across Ad serotypes and subgroups.
In this report, we carried out a systematic analyses of interaction between E3-19K proteins of Ad serotypes 7 and 35 (subgroup B), 5 (subgroup C), 37 (subgroup D), and 4 (subgroup E) and HLA-A (A*0301, A*1101, A*3101, A*3301, and Aw*6801), -B (B*0702 and B*0801), and -C (Cw*0304 and Cw*0401) molecules using site-directed mutagenesis, native gel, SPR, and flow cytometry. A molecular and cellular characterization of E3-19K proteins across serotypes and subgroups will provide a more indepth understanding of its immunomodulatory function and will also generate knowledge relevant for advances in Ad pathogenesis.
EXPERIMENTAL PROCEDURES
Cell lines and mAbs-The human HLA-A and -B negative B-cell line C1R stably expressing HLA-A*1101 (A11/C1R; a gift from Dr. R. Gavioli, University of Ferrara, Ferrara, Italy) and HLA-A*3101 (A31/C1R (31)) were maintained in RPMI 1640 (Invitrogen) containing 200 µg/ml hygromycin B (Mediatech) and 300 µg/ml G418 (Calbiochem). W6/32 (Abcam), anti-HLA-A11 (One Lambda), and anti-HLA-A31 (One Lambda) were used as primary Abs, FITC-conjugated rat anti-mouse IgG (eBioscience) and FITCconjugated goat anti-mouse IgM (Jackson ImmunoResearch Laboratories) were used as secondary Abs in flow cytometry. The P33 antibody (directed against amino acids 45 to 59 of Ad2 E3-19K) (gift from Dr. W. Wold, Saint Louis University School of Medicine, Saint Louis, MO) was used in immunobloting.
Cloning and Expression-Viral DNA was isolated from Ad37 (strain GW; a gift from J. Chodosh, Harvard Medical School, Boston, MA) by digestion with proteinase K (100 µg/ml) (Invitrogen) at 37°C for 1 hour in 10 mM Tris, 1 mM EDTA, 0.6% SDS (pH 8.0) followed by phenol-chloroform extraction and ethanol precipitation. The cDNA encoding the signal peptide and ER-lumenal domain (residues 1-95) of Ad37 E3-19K (referred to as Ad37 E3-19K) with a C-terminal (His) 6 sequence was generated by PCR using the isolated DNA of Ad37 as a template and the primers 5'-ACTGGATCCATGCTGGGTAAGACATTGTG G-3' (forward), and 5'-CCGGAATTCTCAATGGTGATGGTGATGATG CTTGGTAGGGGGCCACAAGC-3' (reverse). Similar strategies were used to clone Ad7 (residues 1-109), Ad35 (residues 1-109), Ad5 (residues 1-101), and Ad4 (residues 1-108) E3-19K proteins (the viral DNA of Ad7, Ad35, Ad5, and Ad4 were gifts of Drs. E.F. Pedersen (Cornell University Medical College, New York, NY), M. Horwitz (deceased), and W. Wold). Ad2 E3-19K (residues 1-100) was generated as described previously (30) . The cDNA encoding Ad2 E3-19[K91E] (residues 1-100) was generated by the QuikChange site-directed mutational approach (Stratagene) using the Ad2 E3-19K/pFastBac plasmid as template. Recombinant, soluble E3-19K proteins were expressed using the Bac-to-Bac baculovirus expression system (Invitrogen) and purified as described previously (30) .
Expression plasmids for the ER-lumenal domains of HLA-A*0301, -A*1101, -A*3101, -A*3301, -Aw*6801, -B*0702, -B*0801, -Cw*0304, and -Cw*0401 heavy chains have been described previously (31) . The cDNAs encoding the ER-lumenal domains of HLA-A*1101[G56R], -A*1101[E177K], and -A*1101[G56R,E177K] heavy chains were generated by PCR using the QuikChange site-directed approach and the plasmids of HLA-A*1101 heavy chain as template (34) . Plasmids harboring the correct DNA sequence were transformed into competent BL21(DE3)pLysS cells. Recombinant class I heavy chains and β 2 -microglobulin (β 2 m) were expressed as inclusion bodies in BL21(DE3)pLysS cells. Inclusion bodies were washed and solubilized in urea as described previously (35) .
The cDNA of full-length HLA-A*1101[E177K] heavy chain was generated by the QuikChange approach using the plasmid pCR2.1-TOPO/HLA-A*1101 (a gift from Dr. P. Parham, Stanford University School of Medicine, Standford, CA) as template, followed by insertion into the HindIII and XbaI restriction sites of the pcDNA3.1 vector (Invitrogen). The plasmid was linearized with BglII followed by transfection into C1R cells by electroporation as described previously (31) . Stable transfectants expressing HLA-A*1101[E177K] were isolated by selection in 600 µg/ml G418 for 2-3 weeks. The cell-surface expression of HLA-A*1101[E177K] was determined by flow cytometry (see below).
The P631 plasmid was used for expression of full-length Ad2 E3-19K as described previously (36) . The cDNA of full-length Ad2 E3-19K[K91E] was generated by the QuikChange approach using the P631 plasmid as template. The 
Viruses and infection-Ad2 and H2dl801
(H2dl801 has a deletion spanning the Ad2 E3-19K gene coding region (37)) (a gift from Dr. W. Wold) were grown in HeLa S3 cells as described previously (31) . Viruses were purified using the Adeno-X virus purification kit (Clontech) as described previously (31) . A11/C1R and A11[E177K]/C1R cells (2.5 × 10 6 cells) were infected with Ad2 and H2dl801, respectively, at an estimated multiplicity of infection in the range of 60 to 100 in serum-free RPMI 1640. After 1 h, 4 ml of RPMI 1640 containing 10% FBS was added to the cells. Mock infections (infection with serum-free RPMI 1640) were carried out in an identical manner. Mock-, Ad2-and H2dl801-infected transfectants were harvested at 48 h postinfection. Levels of cell-surface expression of HLA-A*1101 and HLA-A*1101[E177K] were determined by flow cytometry (see below). In vitro reconstitution of MHC Class I Molecules-Recombinant, soluble MHC class I molecules were assembled from the inclusion bodies of class I heavy chains and β 2 m (or biotinylated β 2 m) in the presence of synthetic peptides in an oxidative refolding buffer (35) . Refolded β 2 m was biotinylated as described previously (31) . The MHC I-restricted peptides used for refolding have been described previously (31) . Proteins were purified on a Superdex 200 HR 10/30 column in 20 mM Tris and 150 mM NaCl (pH 7.5). Surface Plasmon Resonance-Quantitative analysis of interaction in E3-19K/MHC I pairs were performed using SPR at 20°C on a Biacore T100 instrument as described previously (31) . Biotinylated MHC class I molecules were immobilized on a streptavidin-coated sensor chip (Series S Sensor chip SA, certified) at a density of ~750-800 resonance unit using a stock solution (~30 nM) in HBS-EP (10 mM Hepes, 150 mM NaCl, 3 mM EDTA, and 0.05% Surfactant P20 (pH 7.4)) at a flow rate of 60 µl/minute. Uncoupled streptavidin sites were blocked with biotin (30 µl/minute for 1 minute). Solutions of E3-19K proteins (2.5 nM to 10 µM) were injected over the sample and control flow cells (60 µl/minute for 4 minutes) and binding responses (with control responses automatically subtracted) were recorded. Binding surfaces were regenerated with HBS-EP. Equilibrium dissociation constants were determined by plotting binding responses at steady state versus E3-19K concentrations based on a 1:1 Langmuir binding model using the Biacore T100 evaluation software (version 2.0.1, Biacore).
Native Gel Band-Shift Assay-E3-19K

RESULTS
Expression and Characterization of E3-19K Proteins of Different Serotypes and Subgroups-
We generated baculovirus systems for expression of soluble Ad7 (residues 1-109; subgroup B), Ad35 (residues 1-109; subgroup B), Ad5 (residues 1-101; subgroup C), Ad37 (residues 1-95; subgroup D), and Ad4 (residues 1-108; subgroup E) E3-19K proteins. Proteins were expressed in High Five insect cells at levels ranging from 0.2 to 3 mg purified protein/L cell culture. The proteins migrated as closely spaced bands on SDS-PAGE gel (e.g., see Fig. 1 for Ad37 E3-19K) due to Nglycosylation as demonstrated previously for Ad2 E3-19K (30) . There are four cysteine residues that are absolutely conserved in the ER-lumenal domain of all E3-19K proteins (38) . These cysteine residues are paired, for example, as Cys11/Cys28 and Cys22/Cys83 in Ad2 E3-19K of subgroup C (38) . Interestingly, with the exception of E3-19K proteins of subgroup C, all other E3-19K proteins have two additional conserved cysteine residues in their ER-lumenal domains. We showed previously for Ad7 and Ad37 E3-19K proteins (subgroups B and D, respectively) that these two Cys residues form a disulfide bond (39) . (Table 1) . Interaction between E3-19K proteins of subgroups B, C, and E and the same HLA-A molecules was also determined by SPR ( Table 1 The characterization of Ad37 E3-19K was extended to include interaction with HLA-B and -C molecules. Results from native gel (Fig. 2B) revealed that interaction between Ad37 E3-19K and HLA-B*0702 lead to a protein smear with a very faint band at the expected position of a complex. In contrast, no new band could be seen on the gel for the mixture of Ad37 E3-19K and HLA-B*0801, although a weak smear of the HLA-B*0801 band could be observed. These results are consistent with Ad37 E3-19K interacting, at best, very weakly with HLA-B molecules causing complexes to dissociate during electrophoresis. Analysis of interaction with HLA-C molecules failed to produce new bands on the gel (Fig. 2B) . Instead, intense and focused bands corresponding to uncomplexed Ad37 E3-19K and HLA-C molecules were observed which is consistent with a lack of complex formation. Finally, interaction between Ad37 E3-19K and HLA-B molecules could not be determined reliably by SPR due to weak binding responses, and no interaction could be detected with HLA-Cw*0304 (Table 1) . Taken together, these results show that Ad37 E3-19K manifests locus-specific interaction with MHC class I molecules, i.e., higher avidity with HLA-A relative to -B molecules and no interaction with HLA-C molecules. A SPR analysis of interaction between E3-19K proteins of subgroups B, C, and E and the same HLA-B and -C molecules (Table  1) revealed allele-specific interaction with HLA-B molecules and MHC I locus-specific interaction, as observed for Ad37 E3-19K.
Qualitative and Quantitative Analysis of Interaction Between E3-19K Proteins of Different
Overall, results from native gel and SPR showed that E3-19K proteins of subgroups B, C, D, and E exhibit allele-specific interaction (this was less apparent for Ad37 E3-19K of subgroup D) and MHC I locus-specificity (higher avidity with HLA-A relative to -B molecules and no interaction with HLA-C molecules).
MHC Residue 177 Modulates Differentially the Immunomodulatory Function of E3-19K Proteins of Different Serotypes and Subgroups-Early
studies have identified putative E3-19K binding sites at both the N-terminus of the α1-helix and the C-terminus of the α2-helix (23, 24) . Consistent with this, we showed previously that MHC residue 56, located at the N-terminal end of the α1-helix (Fig.  3) , critically influences the immunomodulatory function of Ad2 E3-19K towards HLA-A molecules (31) . Here, we sought to examine whether MHC residue 177 located at the C-terminal end of the α2-helix (Fig. 3) also plays a role in modulating interaction with E3-19K. Importantly, MHC 177 is a conserved and solvent-exposed Glu residue that occupies a position structurally equivalent to that of MHC 56, i.e., the end of an α-helical segment. These arguments make the negatively charged Glu 177 a potentially "hot spot" for E3-19K interaction on MHC class I molecules.
To assess the role of MHC residue 177, we introduced a Glu 177 -to-Lys 177 [E177K] mutation in HLA-A*1101 heavy chain and monitored interaction first with Ad2 E3-19K (subgroup C) by native gel (Fig. 4A) (Fig. 4B) . The cell-surface expression of HLA-A*1101[E177K] on infected C1R cells, relative to mock-infected cells, was determined to be 83.6%. This is significantly higher than the cell-surface expression of HLA-A*1101 which was determined to be 25.2% under identical conditions. This effect on MHC I expression was specific to E3-19K as infection of C1R cells with H2dl801 virus lacking the Ad2 E3-19K gene (37) had essentially no effect on cell-surface expression of HLA-A*1101[E177K] and HLA-A*1101 (Fig.  4B) 
Lys 91 in Ad2 E3-19K Targets the C-terminus of the α2-helix on MHC Class I Molecules-To date,
we have a rather weak understanding of how E3-19K uses its variable and conserved regions to associate with MHC class I molecules. This knowledge is important as it undoubtedly can help understand the molecular basis of differential interaction in E3-19K/MHC I pairs. In a very recent study (36) , we showed that residues 89 to 93 (M 89 SKQY 93 ) in the conserved region of Ad2 E3-19K are essential for its immunomodulatory function. Here, to gain insights into where this critical stretch of residues from the conserved region preferentially binds to on MHC class I molecules, i.e., at the N-terminus of the α1-helix or the C-terminus of the α2-helix (Fig. 3) , we introduced a Lys 91 -to-Glu 91 mutation in Ad2 E3-19K and monitored interaction with HLA-A*1101 and HLA-A*3101 using a native gel band-shift assay. First, note that Lys 91 is conserved (or substituted by Arg residue) in all E3-19K proteins (numbering of the equivalent Lys or Arg varies with serotypes) thus suggesting an important functional role for this residue. Second, as shown in Fig. 3 , the N-terminus of the α1-helix in HLA-A*1101 has Gly 56 while that in HLA-A*3101 carries Arg 56 , and the C-terminus of the α2-helix in both of these alleles carries Glu 177 . Finally, we showed previously that Ad2 E3-19K binds strongly to HLA-A*1101 but considerably more weakly to HLA-A*3101 (32) (see Table 1 ). Taken together, an analysis of interaction between E3-19K[K91E] and HLA-A*1101 and HLA-A*3101 will likely allow to distinguish just how E3-19K uses a critical stretch of residues from its conserved region to target MHC class I molecules, i.e. through interactions at the N-terminus of the α1-helix or the C-terminus of the α2-helix.
The incubation mixtures of Ad2 E3-19K (lane 1 in Our data from native gel were extended by a quantitative analysis of interaction in Ad2 E3-19K[K91E]/MHC I pairs using SPR ( (Fig. 3) (Fig. 5B) ; 77.2% versus 83.2%, respectively. These results suggest that for intrinsically weak complexes such as the Ad2 E3-19K/HLA-A*3101 complex, effects that further weaken binding affinities do not necessarily translate into markedly higher levels of MHC I cell-surface expression.
Taken together, these biochemical and functional analyses have provided evidence that Lys 91 in the conserved region of Ad2 E3-19K is functionally important, and that this residue most likely associates with MHC class I molecules through interactions at the C-terminus of the α2-helix rather than the N-terminus of the α1-helix.
DISCUSSION
A key finding from our characterization of interaction in E3-19K/MHC I pairs is that E3-19K proteins of subgroups B, C, and E display allelespecific interaction with HLA-A and -B molecules; this effect was less obvious for Ad37 E3-19K of subgroup D (at least with this particular set of HLA-A and -B molecules). In a previous study (31 and see Table 1 ), we showed that Ad2 E3-19K displays allele-specific interaction with HLA-A molecules and, importantly, that this specificity correlates (in a negative way) with levels of MHC I expression on Ad2-infected C1R cells. This functional link is further supported here from our data on the differential association of Ad2 E3-19K with HLA-A*1101 relative to both HLA-A*1101[E177K] and Ad2 E3-19K[K91E] mutants. Thus, allele-specific interaction is a common property of E3-19K proteins and binding affinities correlate (in a negative way) with levels of MHC I cell-surface expression on infected cells. As expected, our data also indicated that this correlation is less evident for E3-19K/MHC I pairs that have intrinsically weak affinities, i.e., intrinsically high levels of MHC I cell-surface expression.
Our results also indicate that the allelespecificity of E3-19K proteins for HLA-A molecules is remarkably similar for serotypes of subgroup B as well as subgroup C. Furthermore, our results indicated that Ad37 E3-19K of subgroup D has the weakest binding affinities, while Ad4 E3-19K of subgroup E has the highest binding affinities for HLA-A molecules. Interestingly, it was reported previously that immunoprecipitates of MHC class I molecules from Ad-infected 293 cells co-precipitated Ad2 E3-19K (subgroup C) but not Ad19a E3-19K (subgroup D) (40) . Because the amino acid sequence of Ad19a E3-19K is identical to that of Ad37 E3-19K, this result is consistent with our finding that Ad37 E3-19K binds very weakly to MHC class I molecules. From these studies, we infer that the different MHC I binding properties of E3-19K proteins are the manifestation of differences in key amino acids at the E3-19K/MHC I interface (see model).
Our binding data also showed that E3-19K proteins of subgroups B, C, D, and E display the same locus-specific interaction with MHC class I molecules; stronger affinities with HLA-A compared to HLA-B molecules, and no interaction with HLA-C molecules. This ability of E3-19K proteins to distinguish between MHC gene products may represent a survival mechanism evolved by Ads to selectively manipulate host CTL and natural killer (NK) cell functions. Indeed, given that HLA-A and -B molecules present viral peptides specifically to receptors on CTLs, and that HLA-C molecules present viral peptides specifically to inhibitory receptors on NK cells (41) , the MHC I locus specificity of E3-19K proteins may predispose Ads to avoid clearance by both CTLs and NK cells. Other viral immunomodulatory proteins such as the Kaposi's sarcoma-associated herpes virus K5 protein (42) and Nef from HIV-1 (43) display the same MHC I locus specificity, a property that has been shown to protect virally infected cells from lysis by NK cells (42, 43) . Note that this potential inhibitory mechanism of NK cells is distinct from that proposed recently by McSharry et al. in which E3-19K sequesters MIC A/B molecules, i.e., the ligands of the activating NK receptor NKG2D (44) .
From our binding and cell-based studies, we identified MHC residue 177 in HLA-A*1101 as a critical residue for the immunomodulatory function of E3-19K proteins. More specifically, we showed that the extent of MHC 177 modulating effects on E3-19K proteins varies with serotypes and subgroups, with serotypes of subgroup B being less sensitive to modulation than those of subgroups C, D, and E. Studies of interaction between HLA-A*3101 and E3-19K proteins also allowed us to conclude that, in a manner similar to MHC 177, MHC 56 differentially modulates the MHC I binding function of E3-19K proteins. Importantly, a characterization of interaction between Ad7 E3-
19K
and the double-mutant HLA-A*1101[G56R,E177K] showed that MHC residues 56 and 177 are both part of the Ad7 E3-19K/HLA-A*1101 interface, with MHC 56 being a more dominant contact site. Interestingly, the backbone-to-backbone distance between MHC residues 56 and 177 (see Fig. 3 ) is 19.8Å, and assuming that E3-19K adopts an immunoglobulin (Ig)-like structure (45), its longest dimension would be roughly 33Å (approximated from the xray structures of Ig-like proteins such as β 2 m, US2, and the α3-domain of MHC class I heavy chain). Thus, it is entirely reasonable to suggest that the E3-19K structure can span the distance of 19.8Å. This analysis further supports our experimental findings that MHC residues 56 and 177 are both contacts sites in the Ad7 E3-19K/HLA-A*1101 complex.
On the basis of our data, we propose a model of interaction in E3-19K/MHC I pairs in which all E3-19K proteins establish evolutionally conserved interactions with MHC residues at both the Nterminus of the α1-helix and the C-terminus of the α2-helix of the peptide-binding groove. As suggested by our data, E3-19K proteins most likely use residues from its conserved region, such as the conserved Lys 91 , to mediate interaction with conserved MHC residues, such as Glu 177 , at the Cterminal end of the α2-helix. Note that there are at least two other conserved and negatively charged, solvent-exposed MHC residues at the N-terminal end of the binding groove, namely Glu 53 and Glu 173 (see Fig. 3 ), that may also be important for interaction with conserved residues in E3-19K proteins.
These evolutionally conserved interactions would provide a basal level of stabilizing energy to the E3-19K/MHC I association. In our model, we also suggest that these interactions are supplemented by other important contacts at both the N-terminus of the α1-helix and the C-terminus of the α2-helix of the groove that involve residues from the variable region of E3-19K. These contacts would contribute additional binding energy to the E3-19K/MHC I association, the extent of which can vary with serotypes and subgroups depending on the complementarity of the interacting surfaces. Consequently, and as supported by our data, in order to achieve optimal stabilizing interaction at the E3-19K/MHC I interface, either the N-terminus of the α1-helix or the C-terminus of the α2-helix will serve as a dominant binding region in different E3-19K/MHC I pairs. This view on the conserved and variable regions in the E3-19K/MHC I association accounts for why 1. E3-19K proteins of subgroup B, or subgroup C, which have high levels of sequence homology in their variable regions, display similar allele-specificity towards HLA-A molecules; and 2. E3-19K proteins of different subgroups, which show considerably lower levels of sequence homology in their variable regions, display distinctively different binding affinities (K d values) for a given HLA-A molecule.
The critical role of MHC class I molecules in host antiviral immunity has put tremendous pressure on viruses to evolve escape mechanisms from immune surveillance. For Ads, this is achieved through the intriguing E3-19K protein that targets MHC class I molecules for retention in the ER. In this report, we have provided new information on the MHC I binding properties of E3-19K proteins of different serotypes and subgroups. From this, a picture is emerging on how E3-19K, with a unique arrangement of variable and conserved domains, mediates interaction with its cellular target. This knowledge contributes to move forward our understanding at the molecular level of E3-19K function. Also, our results showing major differences in the strength of interaction in different E3-19K/MHC I pairs more firmly establish the notion that this association plays an important role in the pathogenesis of Ads. In a clinical setting, information on Ad serotypes and subgroups and HLA background of immunocompromised patients is potentially useful to identify patients who may be at higher risks of developing Ad diseases. 
